Food and Drug Administration
January 14, 2003
Slides
Replagal™
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Replagal BLA 103977 Transkaryotic Therapeis, Inc. (HTM) (PPT)
Replagal™ Gene Activated Human aGalactosidase, Introduction, FDA (HTM) (PPT)
Agalsidase Alfa for Treatment of Fabry Disease, Transkaryotic Therapies, Inc. (HTM) (PPT)